Int. J. Mol. Sci. 2013, 14(6), 11402-11423; doi:10.3390/ijms140611402
Review

Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma

1 Department of Urology, Experimental Urology (267), University Medical Centre St. Radboud, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands 2 Department of Nuclear Medicine (756), University Medical Centre St. Radboud, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands 3 Department of Urology (659), University Medical Centre St. Radboud, P.O. Box 9101, Nijmegen 6500 HB, The Netherlands
* Author to whom correspondence should be addressed.
Received: 28 April 2013; in revised form: 14 May 2013 / Accepted: 15 May 2013 / Published: 29 May 2013
(This article belongs to the Special Issue Molecular Research in Urology)
PDF Full-text Download PDF Full-Text [963 KB, uploaded 29 May 2013 13:50 CEST]
Abstract: Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear cell type (ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX expression in ccRCC and excellent targeting capability of mAbG250 in animal models led to the initiation of the clinical evaluation of mAbG250 in (metastatic) RCC (mRCC) patients. Clinical studies confirmed the outstanding targeting ability of mAbG250 and cG250 PET imaging, as diagnostic modality holds great promise for the future, both in detecting localized and advanced disease. Confirmation of the results obtained in the non-randomized clinical trials with unmodified cG250 is needed to substantiate the value of cG250 treatment in mRCC. cG250-Based radio immuno-therapy (RIT) holds promise for treatment of patients with small-volume disease, and adjuvant treatment with unmodified cG250 may be of value in selected cases. In the upcoming years, ongoing clinical trials should provide evidence for these assumptions. Lastly, whether cG250-based RIT can be combined with tyrosine kinase inhibitors, which constitutes the current standard treatment for mRCC, needs to be established.
Keywords: CAIX; monoclonal antibody; G250; girentuximab; clear cell renal cell carcinoma; RCC; radioimmunotherapy; imaging

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Oosterwijk-Wakka, J.C.; Boerman, O.C.; Mulders, P.F.A.; Oosterwijk, E. Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma. Int. J. Mol. Sci. 2013, 14, 11402-11423.

AMA Style

Oosterwijk-Wakka JC, Boerman OC, Mulders PFA, Oosterwijk E. Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2013; 14(6):11402-11423.

Chicago/Turabian Style

Oosterwijk-Wakka, Jeannette C.; Boerman, Otto C.; Mulders, Peter F.A.; Oosterwijk, Egbert. 2013. "Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma." Int. J. Mol. Sci. 14, no. 6: 11402-11423.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert